Business
Exicure to Participate in Upcoming Scientific Conferences
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical
About this update from Exicure, Inc.
[{"type":"text","content":" CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nExicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced participation in the following scientific conferences during the month of September:\n\nTIDES USA 2021\nPoster presentation: \"Biodistribution of Spherical Nucleic Acids in the Rat CNS Following ICM and IT Delivery\"\nSeptember 20 – 30, 2021\n\n17th Annual Meeting of the Oligonucleotide Therapeutics Society\nPoster presentation: \"Development of Spherical Nucleic Acids Targeting FXN for the Treatment of Friedreich's Ataxia\"\nSeptember 26 – 29, 2021\n\nPosters will go live at the start of the conference and will be available to conference attendees.\n\nExicure will add the posters to its website after each conference.\n\nAbout Exicure, Inc.\nExicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNA–based therapeutic candidate, for the intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA. www.exicuretx.com\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210915005117/en/\n\nMedia Contact:\nKaren Sharma\nMacDougall\n781-235-3060\[email protected]\n\nSource: Exicure, Inc.","length":4086,"tagName":"div"}]